NHS England admits its paperwork hid that Palantir staff can see identifiable patient data
NHS England admits its paperwork hid that Palantir staff can see identifiable patient data

NHS England has admitted that a key data-protection document misstated who could see patients’ medical records. It did not disclose the whole arrangement. Staff at Palantir, the US data-analytics firm, can view identifiable patient data inside part of …

Everyone’s building a ‘GPT for cells.’ Relation’s bet is manufacturing the data to train it.
Everyone’s building a ‘GPT for cells.’ Relation’s bet is manufacturing the data to train it.

The race to build an AI “foundation model of the cell” has a fuel problem. The biological data needed to train one is scarce, messy and inconsistent. Relation Therapeutics thinks the answer is to manufacture that data itself, and GSK is paying up to $1…

This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials
This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials

Most AI imaging startups build one model per disease. A Cambridge company has raised $20m to build a single model for the whole chest. Then it can spin the rest out of that. Qureight makes AI imaging tools for lung and heart clinical trials. It closed …

DeepMind won a Nobel for AlphaFold. Then it broke up the team.
DeepMind won a Nobel for AlphaFold. Then it broke up the team.

Less than a year ago, AlphaFold won Google DeepMind a Nobel Prize. Now DeepMind has taken the team that built it apart. The lab has reassigned most of the original AlphaFold-paper authors over the past year, the Financial Times reported. Nearly a quart…

Anthropic spent a year buying biology talent. Its newest partner says the bottleneck isn’t science.
Anthropic spent a year buying biology talent. Its newest partner says the bottleneck isn’t science.

ICON plc has agreed a multi-year collaboration with Anthropic to put Claude across the clinical trial process. The Dublin company is a contract research organisation, which means pharmaceutical firms pay it to run their trials. It employed roughly 40,2…

Only 27% of US hospitals can run an EEG. Epitel raised $26m for the rest
Only 27% of US hospitals can run an EEG. Epitel raised $26m for the rest

Epitel has raised $26m in a Series B round to expand a wireless EEG system that patients wear at home. Catalyst Health Ventures and Genoa Ventures co-led the round. The Salt Lake City company says it will spend the money on sales, marketing and distrib…

The FDA just picked its first company to sell an unauthorised device to Medicare patients
The FDA just picked its first company to sell an unauthorised device to Medicare patients

The US Food and Drug Administration named Dexcom as the first manufacturer selected for its Technology-Enabled Meaningful Patient Outcomes pilot on Tuesday. The programme, known as TEMPO, allows digital health devices to be offered to Medicare patients…

Dopl Technologies raises $6.3M to bring remote robotic ultrasound to rural hospitals
Dopl Technologies raises $6.3M to bring remote robotic ultrasound to rural hospitals

Dopl Technologies raised $6.3 million in seed funding led by SpringTide Ventures to advance a telerobotic ultrasound platform toward FDA clearance. The system, called Traverse, lets sonographers remotely operate a robotic arm via haptic controllers and…

OpenAI wants your medical records, and says its AI is ‘better than clinician level’
OpenAI wants your medical records, and says its AI is ‘better than clinician level’

OpenAI wants to be in the room for your next diagnosis. On Thursday it began rolling out ChatGPT Health to every logged-in US adult. The chatbot can now connect to your Apple Health data and medical records, the company said. It can then draw on them i…

A nervous Dassault is spending $2bn on AI, in the division dragging it down
A nervous Dassault is spending $2bn on AI, in the division dragging it down

Dassault Systèmes is one of Europe’s largest software companies, and it is having an anxious year. Its shares are down about a quarter this year. It pushed out its chairman in February. And investors worry that a new wave of AI could hollow out its mai…